HER2 抑制剂市场规模、份额、成长分析（按疗法、应用、最终用户、地区）- 产业预测（2025 年至 2032 年）

预计 2023 年全球 HER2 抑制剂市场规模将达到 92 亿美元，并从 2024 年的 101.4 亿美元成长到 2032 年的 220.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 10.2%。

乳癌和胃癌（尤其是 HER2 阳性变异型）发生率的上升，推动了全球对 HER2 抑制剂的需求，而 HER2 抑制剂对于标靶癌症治疗至关重要。这些恶性肿瘤的存活率较低，因此旨在改善患者预后的精准治疗日益增多。免疫组织化学 (IHC) 和萤光原位杂合反应(FISH) 等诊断技术的进步提高了早期检测率，进一步增强了 HER2 抑制剂的应用。同时，新型抗体药物复合体(ADC) 和生物相似药的推出降低了药品成本，扩大了重要治疗的可及性。美国FDA 和 EMA 的监管支持以及 HER2标靶治疗药物的快速核准途径，加强了临床开发，使 HER2 抑制剂成为肿瘤学产品组合的焦点，推动了市场成长。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析
• 技术分析
• 案例研究

HER2 抑制剂市场规模（依治疗类型和复合年增长率） (2025-2032)

• 市场概览
• 单药治疗
  • 单药 HER2 抑制剂
  • HER2标靶治疗
• 联合治疗
  • 与 HER2 抑制剂化疗合併
  • 与HER2抑制剂标靶治疗联合
  • 与 HER2 抑制剂荷尔蒙疗法合併

HER2 抑制剂市场规模（按应用划分）及复合年增长率（2025-2032）

• 市场概览
• 鳞状细胞癌
• 腺癌
• 大细胞癌
• 乳癌
• 其他用途

HER2 抑制剂市场规模（依最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 诊所
• 其他最终用户

HER2 抑制剂市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Genentech（USA）
• Hoffmann-La Roche（Switzerland）
• Pfizer Inc.（USA）
• AstraZeneca（United Kingdom）
• Novartis AG（Switzerland）
• Amgen Inc.（USA）
• Eli Lilly and Company（USA）
• Biogen Inc.（USA）
• Sanofi SA（France）
• Symbio Pharmaceuticals（USA）
• Puma Biotechnology（USA）
• Ipca Laboratories（India）

结论和建议

Global HER2 Inhibitors Market size was valued at USD 9.2 billion in 2023 and is poised to grow from USD 10.14 billion in 2024 to USD 22.05 billion by 2032, growing at a CAGR of 10.2% during the forecast period (2025-2032).

The rising prevalence of breast and gastric cancers, particularly HER2-positive variants, is driving the global demand for HER2 inhibitors, crucial for targeted cancer therapies. These aggressive cancers exhibit lower survival rates, prompting an increase in precision treatments aimed at improving patient outcomes. Advancements in diagnostic technologies such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are enhancing early detection, further elevating the use of HER2 inhibitors. Concurrently, the introduction of new antibody-drug conjugates (ADCs) and biosimilars is reducing drug costs and expanding access to vital care. Regulatory support from the U.S. FDA and EMA, alongside expedited approval pathways for HER2-targeted therapies, is bolstering clinical development, positioning HER2 inhibitors as a focal point in oncology portfolios and driving market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global HER2 Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global HER2 Inhibitors Market Segments Analysis

Global HER2 Inhibitors Market is segmented by Treatment, Application, End User and region. Based on Treatment, the market is segmented into Monotherapy and Combination Therapy. Based on Application, the market is segmented into Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer and Other Applications. Based on End User, the market is segmented into Hospitals, Clinics and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global HER2 Inhibitors Market

The rising incidence of HER2-positive cancers, particularly in breast and gastric cancer cases, significantly drives the growth of the global HER2 inhibitors market. Enhanced education and awareness, alongside advancements in diagnostic capabilities, have led to improved early detection rates, resulting in a larger pool of patients requiring HER2-targeted therapies. This expanding patient demographic is not only increasing the market share for HER2 inhibitors globally but is also fueling the ongoing demand for improved and innovative HER2 inhibitor treatments within healthcare systems worldwide. Consequently, the need for advanced therapies continues to rise, further establishing the significance of this market segment.

Restraints in the Global HER2 Inhibitors Market

The Global HER2 Inhibitors market faces significant constraints primarily due to the high costs associated with these therapies. Although HER2 inhibitors offer substantial clinical benefits, their exorbitant prices severely limit access, especially in low- and middle-income countries. This financial burden affects healthcare systems and patients alike, creating a significant barrier to accessing these potentially life-saving treatments. Consequently, the high treatment costs hinder market growth and impede equitable access to advanced oncological therapies on a global scale. As a result, the potential for widespread adoption and improved patient outcomes remains significantly restricted.

Market Trends of the Global HER2 Inhibitors Market

The global HER2 inhibitors market is witnessing significant growth, propelled by advancements in targeted therapy and the rise of personalized medicine. Innovative HER2 inhibitors are being developed with enhanced specificity and efficacy, tailored specifically for HER2-positive cancers. This evolution not only aims to improve patient outcomes but also seeks to minimize adverse side effects associated with conventional treatments. The increasing prevalence of HER2-positive tumors, coupled with a growing emphasis on individualized treatment plans, is driving demand for these therapeutics. As a result, pharmaceutical companies are intensifying research and development efforts, further shaping the landscape of the HER2 inhibitors market for the foreseeable future.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies

Global HER2 Inhibitors Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Monotherapy
  • Single-Agent HER2 Inhibitors
  • Targeted HER2 Therapies
• Combination Therapy
  • HER2 Inhibitors Combined With Chemotherapy
  • HER2 Inhibitors Combined With Targeted Therapies
  • HER2 Inhibitors Combined With Hormonal Therapies

Global HER2 Inhibitors Market Size by Application & CAGR (2025-2032)

• Market Overview
• Squamous Cell Carcinoma
• Adenocarcinoma
• Large Cell Carcinoma
• Breast Cancer
• Other Applications

Global HER2 Inhibitors Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Other End Users

Global HER2 Inhibitors Market Size & CAGR (2025-2032)

• North America (Treatment, Application, End User)
  • US
  • Canada
• Europe (Treatment, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Genentech (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Symbio Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Puma Biotechnology (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipca Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations